Rinath Jeselsohn
Affiliations: | Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA, United States |
Google:
"Rinath Jeselsohn"Parents
Sign in to add mentor
BETA: Related publications
See more...
Publications
|
You can help our author matching system! If you notice any publications incorrectly attributed to this author, please sign in and mark matches as correct or incorrect. |
| Guarducci C, Nardone A, Russo D, et al. (2024) Selective CDK7 inhibition suppresses cell cycle progression and MYC signaling while enhancing apoptosis in therapy-resistant estrogen receptor positive breast cancer. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research |
| Goldberg J, Qiao N, Guerriero JL, et al. (2024) Estrogen Receptor Mutations as Novel Targets for Immunotherapy in Metastatic Estrogen Receptor-Positive Breast Cancer. Cancer Research Communications |
| Tarantino P, Gupta H, Hughes ME, et al. (2023) Author Correction: Comprehensive genomic characterization of HER2-low and HER2-0 breast cancer. Nature Communications. 14: 8321 |
| Tarantino P, Gupta H, Hughes ME, et al. (2023) Comprehensive genomic characterization of HER2-low and HER2-0 breast cancer. Nature Communications. 14: 7496 |
| Cheng YC, Stein S, Nardone A, et al. (2023) Mathematical modeling identifies optimum palbociclib-fulvestrant dose administration schedules for the treatment of estrogen receptor-positive breast cancer patients. Cancer Research Communications |
| Jeselsohn R, Polyak K. (2023) HATS off to KAT6A/B inhibitors: A new way to target estrogen-receptor-positive breast cancer. Cell Chemical Biology. 30: 1183-1185 |
| Coombes RC, Howell S, Lord SR, et al. (2023) Author Correction: Dose escalation and expansion cohorts in patients with advanced breast cancer in a Phase I study of the CDK7-inhibitor samuraciclib. Nature Communications. 14: 4741 |
| Pan M, Solozobova V, Kuznik NC, et al. (2023) Identification of an Imidazopyridine-based Compound as an Oral Selective Estrogen Receptor Degrader for Breast Cancer Therapy. Cancer Research Communications. 3: 1378-1396 |
| Charles Coombes R, Howell S, Lord SR, et al. (2023) Dose escalation and expansion cohorts in patients with advanced breast cancer in a Phase I study of the CDK7-inhibitor samuraciclib. Nature Communications. 14: 4444 |
| Fu X, Pereira R, Liu CC, et al. (2023) High FOXA1 levels induce ER transcriptional reprogramming, a pro-metastatic secretome, and metastasis in endocrine-resistant breast cancer. Cell Reports. 42: 112821 |